Parkinson Disease
|
0.600 |
Biomarker
|
disease |
RGD |
Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats.
|
18289173 |
2008 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Absence of opiate rewarding effects in mice lacking dopamine D2 receptors.
|
9252189 |
1997 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia.
|
9247268 |
1997 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice.
|
9717839 |
1998 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Activity, non-selective attention and emotionality in dopamine D2/D3 receptor knock-out mice.
|
11864730 |
2002 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Neuroprotective role of dopamine against hippocampal cell death.
|
11069974 |
2000 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors.
|
7566118 |
1995 |
Parkinson Disease
|
0.600 |
Therapeutic
|
disease |
CTD_human |
ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
|
8558425 |
1996 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, we suggest that L-DOPA may attenuate the neuropathology of PD by regulating signaling related to DRD2 in neuronal cells under α-syn-induced toxicity.
|
28687316 |
2017 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our results show a significant association between the dopamine D2 receptor gene polymorphism Taq IA and SOS in PD.
|
15390060 |
2004 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The importance of dopamine D2 receptors (DRD2) for central nervous dopaminergic signalling makes variants in the DRD2 gene potential modulators of the risk or course of various behavioural, psychiatric or neurologic diseases (e.g. addiction, schizophrenia, Parkinson's disease).
|
19512960 |
2009 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease.
|
12722176 |
2003 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Previously, we found a significant association between the dopamine D2 receptor gene polymorphism Taq IA and sudden onset of sleep in patients with Parkinson disease.
|
16124668 |
2005 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.
|
29466326 |
2018 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Since genetic factors could play a role in determining the occurrence of these problems, the aim of the present study was to investigate whether possible functional polymorphisms among DRD2 and ANKK1 genes are associated with the risk of developing dyskinesia and motor fluctuations in Parkinson's disease patients.
|
23171335 |
2012 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association between Dopamine receptor D type 2 (DRD2) dinucleotide short tandem repeat (CA<sub>n</sub>-STR) and Dopamine receptor D type 3 (DRD3) Ser9Gly polymorphisms and the risk of PD, as well as the possible reasons for PD patients using different doses of DAs, we recruited 168 idiopathic PD patients and 182 controls.
|
27817855 |
2017 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
|
29434188 |
2018 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thus our results do not support a role for the DRD2 locus to develop PD.
|
10515181 |
1999 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, alterations in RGS9-2 may be a key factor in the pathway leading from D2DRs to the side effects associated with the treatment both of psychoses and Parkinson's disease.
|
15728856 |
2005 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We tested for gender-specific interactions between smoking and genetic polymorphisms of monoamine oxidase B (MAO-B) intron 13 (G or A allele), monoamine oxidase A (MAO-A) EcoRV (Yor N allele), and dopamine D2 recepor (DRD2) Taq1B (B1 or B2 allele) in a case-control study of 186 incident idiopathic Parkinson's disease (PD) cases and 296 age- and gender-matched controls.
|
12428723 |
2002 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study, we used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced PD mouse model to investigate whether Drd2 could suppress astrocytic NLRP3 inflammasome activation.
|
29786071 |
2018 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we investigated this effect in Parkinson's disease (PD) patients carrying the DRD2 TaqIA A1 allelic variant.
|
17147698 |
2007 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Further, DRD2 variants have been implicated in Parkinson's disease (PD) and in iatrogenically-induced movement disorders, as well as in certain migraineurs.
|
11256581 |
2000 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We examined the relation between inhibitory ability (measured by the Stop Signal Task) and polymorphisms of COMT Val158Met and DRD2 C957T in patients with idiopathic PD.
|
24749760 |
2014 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Drd2 is also the primary target of both antipsychotics and Parkinson's disease medications.
|
30604007 |
2019 |